(31 days)
The DEKA AGAIN PRO family is a medical laser family intended for:
Alexandrite laser (755nm):
- Temporary hair reduction.
- Stable long-term or permanent hair reduction through selective targeting of melanin in hair follicles.
- Permanent hair reduction is defined as the long-term, stable reduction in the number of hairs regrowing when measured at 6,9 and 12 months after the completion of a treatment regime on all skin types (Fitzpatrick I-VI) included tanned skin.
- Treatment of benign pigmented lesions.
- Treatment of dermatological vascular lesions (such as port-wine stains, hemangiomas, telangiectasias).
Nd:YAG laser (1064nm):
- Removal of unwanted hair for stable long term or permanent hair reduction and for treatment of PFB. The laser are indicated on all Skin Types Fitzapatrick I-VI including tanned skin.
- Photocoaqulation and hemostasis of pigmented and vascular lesions, such as but not limited to, port wine stains, hemangioma, warts, teleangiectasia, rosacea, venus lake, leg veins and spider veins.
- Coagulation and hemostasis od soft tissue.
- Benign pigmented lesions such as, but not limited to, lentigos, (age spots), solar lentigos (sun spots), cafè au lait macules, seborrheic keratosis, nevi, cloasma, verrucae, skin tags, keratosis and plaques.
- Pigmented lesions to reduce lesion size, for patients with lesions that would potentially benefit from aggressive treatment, and for patients with lesions that have not responded to other laser treatments.
- Reduction of red pigmentation in hypertrophic and keloid scars where vascularity is an integral part of the scar.
- Treatment of wrinkles.
The DEKA AGAIN PRO family is a medical laser family equipped with Alexandrite 755nm laser and Nd:YAG 1064nm laser.
The laser sources deliver the laser output through a lens coupled user replaceable optical fiber with a wider range of interchangeable, quick release laser handpieces with electronic spot recognition.
The modifications to the device consist in a restyling of the device (new chassis, cover plastic, dimensions, weight and GUI, removal of Pulsed Light FT handpiece) and in modification to spot size ranges (new spot size available).
The intended use of the modified device, as described in the labelling has not changed as a result of the modifications. Labelling itself has been updated also to include general improvements that have been implemented since predicate device clearance and considered as minor changes.
The provided text describes the 510(k) summary for the DEKA AGAIN PRO family device. It primarily focuses on demonstrating substantial equivalence to a predicate device (DEKA SYNCHRO REPLA:Y family of Laser system, K150516) rather than detailing specific clinical performance studies with acceptance criteria for an AI/ML-driven device's diagnostic performance.
The document states:
- The DEKA AGAIN PRO family is a medical laser system.
- The modifications to the device are primarily cosmetic (new chassis, cover plastic, dimensions, weight, GUI, removal of a handpiece) and a slight modification to spot size ranges.
- The intended use of the modified device, as described in the labeling, has not changed as a result of the modifications.
- The manufacturer is asserting the new device is substantially equivalent to the predicate.
Therefore, the information you're asking for regarding acceptance criteria and performance studies typical for an AI/ML diagnostic device (e.g., sensitivity, specificity, MRMC studies, ground truth establishment) is not present in this 510(k) summary. This document is for a physical medical device (laser) and its review focuses on showing that the changes made to a previously cleared device do not introduce new questions of safety or effectiveness, often through engineering, electrical safety, and software validation testing, rather than new clinical outcome studies.
Based on the provided text, I cannot answer the questions directly as they pertain to the clinical performance evaluation of an AI/ML diagnostic device.
However, I can extract the information that is present regarding testing and conclusions:
1. A table of acceptance criteria and the reported device performance
The document does not provide a table of acceptance criteria for diagnostic performance or reported performance metrics (like sensitivity, specificity, AUC) because it is a laser device, not an AI/ML diagnostic software. The "performance data" section focuses on regulatory compliance:
| Test/Category | Reported Performance |
|---|---|
| Electrical safety and electromagnetic compatibility (EMC) | Conducted according to the following standards: - AAMI/ANSI ES60601-1: Medical Electrical Equipment – Part 1: General Requirements for Basic Safety and Essential Performance. - IEC 60601-1-2: Medical Electrical Equipment – Part 1-2: General Requirements for Basic Safety and Essential Performance – Collateral standard: Electromagnetic Disturbances – Requirements and tests. - IEC 60601-2-22: Medical Electrical Equipment – Part 2-22: Particular requirements for basic safety and essential performance of surgical, cosmetic, therapeutic and diagnostic laser equipment. - IEC 60825-1: Safety of laser products – Part 1: Equipment classification and requirements. (The document implies these tests were passed, as the device received clearance.) |
| Software Validation and Verification Testing | Conducted and documented as recommended by FDA's Guidance for Industry and FDA Staff, "Content of Premarket Submission for Device Software Functions". (The document implies these tests were passed, as the device received clearance.) |
| Clinical Performance | Not applicable/Not performed. The device is cleared based on substantial equivalence to a predicate laser device with unchanged intended use despite minor design modifications. The submission claims general improvements since predicate clearance but does not present new clinical data beyond the predicate's established performance based on its original clearance. |
Regarding the specific questions for an AI/ML diagnostic device:
- Sample sizes used for the test set and the data provenance: Not applicable. No test set for AI/ML performance is described.
- Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g. radiologist with 10 years of experience): Not applicable. No ground truth establishment for AI/ML performance is described.
- Adjudication method (e.g. 2+1, 3+1, none) for the test set: Not applicable. No test set for AI/ML performance is described.
- If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance: Not applicable. This is not an AI/ML assistance device.
- If a standalone (i.e. algorithm only without human-in-the-loop performance) was done: Not applicable. This is not an AI/ML diagnostic algorithm.
- The type of ground truth used (expert consensus, pathology, outcomes data, etc.): Not applicable. No ground truth for AI/ML performance is described.
- The sample size for the training set: Not applicable. This is not an AI/ML diagnostic device.
- How the ground truth for the training set was established: Not applicable. This is not an AI/ML diagnostic device.
In summary, the provided document is a 510(k) summary for a laser surgical instrument (DEKA AGAIN PRO family) demonstrating substantial equivalence to a predicate device, not an AI/ML diagnostic software. Therefore, the detailed performance study information typically required for AI/ML devices is not found here.
{0}------------------------------------------------
Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food & Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.
October 27, 2023
El. En. S.p.A. Paolo Peruzzi Regulatory Affairs Manager Via Baldanzese 17 Calenzano, Fl 50141 Italy
Re: K233090
Trade/Device Name: DEKA AGAIN PRO family Regulation Number: 21 CFR 878.4810 Regulation Name: Laser Surgical Instrument For Use In General And Plastic Surgery And In Dermatology Regulatory Class: Class II Product Code: GEX Dated: September 26, 2023 Received: September 26, 2023
Dear Paolo Peruzzi:
We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
{1}------------------------------------------------
Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).
Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30, Design controls; 21 CFR 820.90, Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4. Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn).
{2}------------------------------------------------
Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/deviceadvice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely.
Tanisha L. Hithe -S Tanisha L. 2023.10.27 Hithe -S 00:30:55 -04'00'
Tanisha Hithe Assistant Director DHT4A: Division of General Surgery Devices OHT4: Office of Surgical and Infection Control Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
{3}------------------------------------------------
Indications for Use
Submission Number (if known)
K233090
Device Name
DEKA AGAIN PRO family
Indications for Use (Describe)
The DEKA AGAIN PRO family is a medical laser family intended for:
Alexandrite laser (755nm):
-
Temporary hair reduction.
-
Stable long-term or permanent hair reduction through selective targeting of melanin in hair follicles.
-
Permanent hair reduction is defined as the long-term, stable reduction in the number of hairs regrowing when measured at 6,9 and 12 months after the completion of a treatment regime on all skin types (Fitzpatrick I-VI) included tanned skin.
-
Treatment of benign pigmented lesions.
-
Treatment of dermatological vascular lesions (such as port-wine stains, hemangiomas, telangiectasias).
Nd:YAG laser (1064nm):
-
Removal of unwanted hair for stable long term or permanent hair reduction and for treatment of PFB. The laser are indicated on all Skin Types Fitzapatrick I-VI including tanned skin.
-
Photocoaqulation and hemostasis of pigmented and vascular lesions, such as but not limited to, port wine stains, hemangioma, warts, teleangiectasia, rosacea, venus lake, leg veins and spider veins.
-
Coagulation and hemostasis od soft tissue.
-
Benign pigmented lesions such as, but not limited to, lentigos, (age spots), solar lentigos (such spots), cafè au lait macules, seborrheic keratosis, nevi, cloasma, verrucae, skin tags, keratosis and plaques.
-
Pigmented lesions to reduce lesion size, for patients with lesions that would potentially benefit from aggressive treatment, and for patients with lesions that have not responded to other laser treatments.
-
Reduction of red pigmentation in hypertrophic and keloid scars where vascularity is an integral part of the scar.
-
Treatment of wrinkles.
Type of Use (Select one or both, as applicable)
Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
Form Approved: OMB No. 0910-0120 Expiration Date: 06/30/2023 See PRA Statement below.
{4}------------------------------------------------
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
{5}------------------------------------------------
510(k) Summary
K233090
AGAIN PRO family – Special 510(k)
Submitter:
El.En. S.p.A. Via Baldanzese, 17 50041 Calenzano (FI), Italy
Contact:
Paolo Peruzzi Regulatory Affairs Manager & Official Correspondent Phone: +39.055.8826807 E-mail: p.peruzzi@elen.it
Date Summary Prepared: October 20, 2023
Device Trade Name:
DEKA AGAIN PRO
Manufacturer:
DEKA M.E.L.A. srl Via Baldanzese, 17 50041 Calenzano (FI), Italy
Common Name:
Medical laser system
Regulation Number:
21 CFR 878.4810
Regulation Name:
Laser Surgical Instrument for use in General and Plastic and in Dermatology
Regulatory Class:
Class II
Product Code:
GEX
{6}------------------------------------------------
Predicate Devices:
DEKA SYNCHRO REPLA:Y family of Laser system (K150516)
Device Description:
The DEKA AGAIN PRO family is a medical laser family equipped with Alexandrite 755nm laser and Nd:YAG 1064nm laser.
The laser sources deliver the laser output through a lens coupled user replaceable optical fiber with a wider range of interchangeable, quick release laser handpieces with electronic spot recognition.
The modifications to the device consist in a restyling of the device (new chassis, cover plastic, dimensions, weight and GUI, removal of Pulsed Light FT handpiece) and in modification to spot size ranges (new spot size available).
The intended use of the modified device, as described in the labelling has not changed as a result of the modifications. Labelling itself has been updated also to include general improvements that have been implemented since predicate device clearance and considered as minor changes.
Intended Use:
The DEKA AGAIN PRO family is intended for:
- Alexandrite 755nm laser source
Temporary hair reduction.
Stable long-term or permanent hair reduction through selective targeting of melanin in hair follicles. Permanent hair reduction is defined as the long-term, stable reduction in the number of hairs regrowing when measured at 6, 9 and 12 months after the completion of a treatment regime, on all skin types (Fitzpatrick I-VI) including tanned skin.
Treatment of benign pigmented lesions.
Treatment of wrinkles.
Photocoagulation of dermatological vascular lesions (such as port-wine stains, hemangiomas, telangiectasias).
Nd:YAG 1064nm laser source
Removal of unwanted hair, for stable long term or permanent hair reduction and for treatment of PFB. The laser is indicated on all Skin Types Fitzpatrick I-VI including tanned skin.
Photocoagulation and hemastatis of pigmented and vascular lesions, such as but not limited to port wine stains, hemangioma warts, teleangiectasia, rosacea, venus lake, leg veins and spider veins.
Coagulation and hemostasis of soft tissue.
{7}------------------------------------------------
Benign pigmented lesions such as, but not limited to, lentigos, (age spots), solar lentigos (sun spots), cafe au lait macules, seborrheic keratosis, nevi, cloasma, verrucae, skin tags, keratosis and plaques.
The laser is indicated for pigmented lesions to reduce lesion size, or patients with lesions that would potentially benefit from aggressive treatment, and for patients with lesions that have not responded to other laser treatments.
The laser is also indicated for the reduction of red pigmentation in hypertrophic and keloid scars where vascularity in an integral part of the scar.
Treatment of wrinkles.
{8}------------------------------------------------
Substantial equivalence discussion:
| Device Trade Name | Subject Device | Predicate Device | Comment |
|---|---|---|---|
| AGAIN PRO family | K150516SYNCHRO REPLA:Y | ||
| Indications for use | Alexandrite 755 nm laser:Temporary hair reduction.Stable long-term or permanent hair reduction throughselective targeting of melanin in hair follicles. Permanenthair reduction is defined as the long-term, stable reductionin the number of hairs regrowing when measured at 6, 9and 12 months after the completion of a treatment.Treatment of benign pigmented lesions.Treatment of wrinkles.Photocoagulation of dermatological vascular lesions (suchas port-wine stains, hemangiomas, telangiectasias).Nd:YAG 1064 nm laser:Removal of unwanted hair, for stable long term orpermanent hair reduction and for treatment of PFB. Thelasers are indicated on all Skin Types Fitzpatrick I-VIincluding tanned skin.Photocoagulation and hemostasis of pigmented andvascular lesions, such as but not limited to port wine stains,hemangioma, warts, teleangiectasia, rosacea, venus lake,leg veins and spider veins.Coagulation and hemostasis of soft tissue.Benign pigmented lesions such as, but not limited to,lentigos, (age spots), solar lentigos (sun spots), café au laitmacules, seborrheic keratosis, nevi, cloasma, verrucae, skintags, keratosis and plaques.The laser is indicated for pigmented lesions to reduce lesion | Alexandrite 755 nm laser:Temporary hair reduction.Stable long-term or permanent hair reduction throughselective targeting of melanin in hair follicles. Permanenthair reduction is defined as the long-term, stable reductionin the number of hairs regrowing when measured at 6, 9 and12 months after the completion of a treatment.Treatment of benign pigmented lesions.Treatment of wrinkles.Photocoagulation of dermatological vascular lesions (such asport-wine stains, hemangiomas, telangiectasias).Nd:YAG 1064 nm laser:Removal of unwanted hair, for stable long term orpermanent hair reduction and for treatment of PFB. Thelasers are indicated on all Skin Types Fitzpatrick I-VIincluding tanned skin.Photocoagulation and hemostasis of pigmented and vascularlesions, such as but not limited to port wine stains,hemangioma, warts, teleangiectasia, rosacea, venus lake, legveins and spider veins.Coagulation and hemostasis of soft tissue.Benign pigmented lesions such as, but not limited to,lentigos, (age spots), solar lentigos (sun spots), café au laitmacules, seborrheic keratosis, nevi, cloasma, verrucae, skintags, keratosis and plaques. | Identical for 755nm laserand 1064nm laser; Pulsedlight FT handpiece is notavailable for Again ProFamily |
{9}------------------------------------------------
| Device Trade Name | Subject DeviceAGAIN PRO family | Predicate DeviceK150516SYNCHRO REPLA:Y | Comment | ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| size, or patients with lesions that would potentially benefitfrom aggressive treatment, and for patients with lesionsthat have not responded to other laser treatments.The laser is also indicated for the reduction of redpigmentation in hypertrophic and keloid scars wherevascularity is an integral part of the scar.Treatment of wrinkles. | The laser is indicated for pigmented lesions to reduce lesionsize, or patients with lesions that would potentially benefitfrom aggressive treatment, and for patients with lesions thathave not responded to other laser treatments.The laser is also indicated for the reduction of redpigmentation in hypertrophic and keloid scars wherevascularity is an integral part of the scar.Treatment of wrinkles.Pulsed light FT handpiece:Permanent hair reduction, photocoagulation of vascularlesions, photothermolysis of blood vessels, treatment ofbenign pigmented lesions.Different wavelength ranges of pulsed light attachment areindicated for the various treatments and skin types, asindicated in the following table:Pulsed lightwavelengthrange Hairreduction Vascularlesions Bloodvessels Pigmentedlesions 500 - 1200 nm - Skin Types I, II Skin Types I, II - 520 - 1200 nm - Skin Type III Skin Type III Skin Types I, II 550 - 1200 nm Skin Types I, II - - Skin Type III 600 – 1200 nm Skin Type III - - - 650 – 1200 nm Skin Type IV - - Skin Type IV | ||||||||||||||||||||||||||||||||
| 755 nm LASER (not available for SYMPHONY) | |||||||||||||||||||||||||||||||||
| Laser Type | Alexandrite | Alexandrite | Identical | ||||||||||||||||||||||||||||||
| Wavelength (nm) | 755nm | 755 nm | Identical |
{10}------------------------------------------------
| Device Trade Name | Subject DeviceAGAIN PRO family | Predicate DeviceK150516SYNCHRO REPLA:Y | Comment |
|---|---|---|---|
| Max Fluence (J/cm²) * | 600 (J/cm²) | 600 (J/cm²) | Identical |
| Handpiece Spot Sizes(diameter millimeter) | 2.5 mm5 mm7 mm10 mm12 mm14 mm15 mm16 mm18 mm20 mm22 mm24 mm30 mm | 2.5 mm5 mm7 mm10 mm12 mm14 mm15 mm16 mm18 mm20 mm22 mm24 mm | Almost identical, differentmaximum spot size butsame fluence range.Change do not affectsafety and effectiveness ofthe device |
| Pulse Duration(milliseconds) | 0.2 to 300 ms | 0.25 to 300 ms | Almost identical, minimumpulse duration is slightlydifferent.Change do not affectsafety and effectiveness ofthe device |
| Pulse Repetition Rate | Up to 12 Hz | Up to 10 Hz | Similar, maximumfrequency is slightly |
| Device Trade Name | Subject DeviceAGAIN PRO family | Predicate DeviceK150516SYNCHRO REPLA:Y | Comment |
| Change do not affectsafety and effectiveness ofthe device | |||
| Skin Cooling System | Yes, optional | Yes, optional | Identical |
| 1064 nm LASER | |||
| Laser Type | Nd:YAG | Nd:YAG | Identical |
| Wavelength (nm) | 1064 nm | 1064 nm | Identical |
| Max Fluence (J/cm²)* | 600 (J/cm²) | 600 (J/cm²) | Identical |
| Handpiece Spot Sizes | 2.5 mm | 2.5 mm | Almost identical, differentmaximum spot size butsame fluence range. |
| (Diameter millimetre) | 5 mm | 5 mm | |
| 7 mm | 7 mm | ||
| 10 mm | 10 mm | Change do not affectsafety and effectiveness ofthe device | |
| 12 mm | 12 mm | ||
| 14 mm | 14 mm | ||
| 15 mm | 15 mm | ||
| 16 mm | 16 mm | ||
| 18 mm | 18 mm | ||
| 20 mm | 20 mm | ||
| 22 mm | 22 mm | ||
| Device Trade Name | Subject DeviceAGAIN PRO family | Predicate DeviceK150516SYNCHRO REPLA:Y | Comment |
| 24 mm | 24 mm | ||
| 30 mm | |||
| Pulse Duration(milliseconds) | 0.2 to 300 ms | 0.25 to 300 ms | Almost identical, minimumpulse duration is slightlydifferent.Change do not affectsafety and effectiveness ofthe device. |
| Pulse Repetition Rate(Hz) | Up to 12 Hz | Up to 10 Hz | Similar, maximumfrequency is slightlydifferent.Change do not affectsafety and effectiveness ofthe device. |
| Skin Cooling System | Yes, optional | Yes, optional | Identical |
{11}------------------------------------------------
{12}------------------------------------------------
*Maximum fluence is not available for all spot sizes.
{13}------------------------------------------------
Performance Data:
Electrical safety and electromagnetic compatibility (EMC)
Electrical safety and EMC testing were conducted on the DEKA AGAIN PRO device, according to the following standards:
- . AAMI/ANSI ES60601-1- Medical Electrical Equipment – Part 1: General Requirements for Basic Safety and Essential Performance.
- IEC 60601-1-2 – Medical Electrical Equipment – Part 1-2: General Requirements for Basic Safety and Essential Performance – Collateral standard: Electromagnetic Disturbances – Requirements and tests.
- . IEC 60601-2-22 – Medical Electrical Equipment – Part 2-22: Particular requirements for basic safety and essential performance of surgical, cosmetic, therapeutic and diagnostic laser equipment.
- IEC 60825-1 – Safety of laser products – Part 1: Equipment classification and requirements.
Software Validation and Verification Testing
Software verification and validation testing were conducted and documented as recommended by FDA's Guidance for Industry and FDA Staff, "Content of Premarket Submission for Device Software Functions".
Conclusion:
Based on the comparison of indications for use and the technological characteristics, we can conclude that DEKA AGAIN PRO device is as safe, as effective, and performs as well as the legally marketed predicate device (K150516).
Additional Information:
None.
§ 878.4810 Laser surgical instrument for use in general and plastic surgery and in dermatology.
(a)
Identification. (1) A carbon dioxide laser for use in general surgery and in dermatology is a laser device intended to cut, destroy, or remove tissue by light energy emitted by carbon dioxide.(2) An argon laser for use in dermatology is a laser device intended to destroy or coagulate tissue by light energy emitted by argon.
(b)
Classification. (1) Class II.(2) Class I for special laser gas mixtures used as a lasing medium for this class of lasers. The devices subject to this paragraph (b)(2) are exempt from the premarket notification procedures in subpart E of part 807 of this chapter, subject to the limitations in § 878.9.